Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics.
Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Progenity Strengthens its Liquidity Position Company received more than $44 million in warrant exercises since August 2021. Current liquidity position provides runway to achieve critical research and development milestones through 2022. SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pro... November 23, 2021
- Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healt... November 15, 2021
- Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results Added important patents further protecting the company’s therapeutic delivery technologies Added strong biotherapeutics capabilities to management team and board of directors Implemented cost-cutting measures expected to result in approximate... November 10, 2021